Libourne, 5th March 2015

Consolidated sales of the Ceva Group reached €766m at the end of 2014, representing growth of 23% and +14.1% at a constant perimeter and exchange rates. Sales grew in all zones and across all species with particularly strong performance being recorded in companion animals (+17.3%) and poultry (+14%).

The group delivered an operational result slightly ahead of the budgeted objective but also continued to make significant investment in R&D where spending exceeded 9% of sales. The integration of Sogeval proved to be a major success with the creation of a new Ceva Sogeval campus in Laval, France and significant growth in sales (+21%) in France of the joint business.

Marc Prikazsky, Ceva's Chairman and CEO commented, "The consistency in our performance is particularly pleasing and stems from our innovative pipeline of products that should continue to drive growth in the years ahead. I'm delighted by the way we were able to integrate Sogeval into the group, with minimal disruption and indeed a very strong result in France."

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…